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Supporting Treatment decision making to
Optimise the Prevention of STROKE in Atrial
Fibrillation: The STOP STROKE in AF study.
Protocol for a cluster randomised controlled trial
Melina Gattellari1,2, John M Worthington1,3,4*, Dominic Y Leung3,5 and Nicholas Zwar2
Abstract
Background: Suboptimal uptake of anticoagulation for stroke prevention in atrial fibrillation has persisted for
over 20 years, despite high-level evidence demonstrating its effectiveness in reducing the risk of fatal and disabling
stroke.
Methods: The STOP STROKE in AF study is a national, cluster randomised controlled trial designed to improve the
uptake of anticoagulation in primary care. General practitioners from around Australia enrolling in this ‘distance
education’ program are mailed written educational materials, followed by an academic detailing session delivered
via telephone by a medical peer, during which participants discuss patient de-identified cases. General practitioners
are then randomised to receive written specialist feedback about the patient de-identified cases either before or
after completing a three-month posttest audit. Specialist feedback is designed to provide participants with support
and confidence to prescribe anticoagulation. The primary outcome is the proportion of patients with atrial
fibrillation receiving oral anticoagulation at the time of the posttest audit.
Discussion: The STOP STROKE in AF study aims to evaluate a feasible intervention via distance education to
prevent avoidable stroke due to atrial fibrillation. It provides a systematic test of augmenting academic detailing
with expert feedback about patient management.
Trial registration: Australian Clinical Trials Registry Registration Number: ACTRN12611000076976.
Keywords: Atrial fibrillation, General practice, Anticoagulation, Decisional support
Background
Atrial fibrillation (AF) is the most common heart
arrhythmia with a prevalence of around 5% in those aged
over 65, increasing to 10% in those older than 75 years
[1]. AF confers the highest risk for ischaemic stroke of
all traditional risk factors, including congestive heart fail-
ure, diabetes, and hypertension [2]. In Australia, at least
one in four patients admitted to hospital with an ischae-
mic stroke has AF [3]. Mortality in stroke patients with
AF is around twice the rate in those without it; by
12 months, 40% of ischaemic stroke patients with AF
will have died [3]. Moreover, survivors of AF-related
stroke spend a significantly longer time in hospital [3].
Meta-analyses of randomised controlled trials of
antithrombotic medication demonstrate that, in the
average AF patient with a 5% chance of an ischaemic
stroke each year, oral anticoagulation with adjusted-dose
warfarin reduces this annual risk by 67%, in relative
terms, to approximately 1.7% [4]. In contrast, antiplatelet
medication, such as aspirin, reduces the risk by only
21%, to approximately 4% [4]. Despite over 20 years of
evidence supporting lifelong anticoagulation as the treat-
ment of choice for most patients with AF [4-6], 50%–
60% of patients do not receive anticoagulants even if
they are at high risk of stroke [7,8]. An Australian study
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of 218 consecutively admitted patients with AF reported
that only 20% were using warfarin on admission [9], al-
though inclusion of an unspecified number of newly
diagnosed AF cases would have influenced the reported
proportion of under use [9]. In a Canadian stroke unit,
90% of admitted ischaemic stroke patients with AF were
not receiving anticoagulation or were insufficiently
anticoagulated at the time of their stroke [10]. In one
Australian stroke unit, 68% of ischaemic stroke patients
with known AF before admission either were not antic-
oagulated or were sub-optimally anticoagulated at the
time of their stroke [11]. This persistent evidence–prac-
tice gap contributes to the burden of preventable stroke.
Clinicians are often reluctant to prescribe anticoagula-
tion for AF, particularly if patients are elderly or have a
heightened risk of falls or other perceived risk of major
bleeding [12-19]. However, many patients considered
unsuitable for anticoagulation also have an elevated risk
of ischaemic stroke, and the risk-benefit trade-off
favours anticoagulation in the majority of patients with
AF [20-24].
Few studies have evaluated implementation strategies
specifically designed to increase the uptake of oral anticoa-
gulation for AF. McAlister et al. [25] reported an increase
in antithrombotic prescribing at three months in general
practice patients receiving a decision aid. The difference
was not sustained at 12 months after randomisation. In a
nonrandomised study of Australian primary healthcare
physicians in one geographical region of Tasmania, guide-
line dissemination followed by academic-detailing visits
significantly increased prescribing rates of adjusted-dose
warfarin compared to a control region [26]. Two other
studies in the primary healthcare setting addressed several
cardiovascular risk factors, without focusing specifically
on AF management [27,28]. Ornstein et al. [27] tested the
effect of computerised guidelines, reminder systems, and
audit and feedback on prescribing behaviour in managing
several cardiovascular risk factors. Posttest differences be-
tween intervention and control groups were not statisti-
cally significant. Another trial found that locally adapted
guidelines, an educational seminar delivered by local opin-
ion leaders, educational materials, and an offer of an edu-
cational outreach visit did not increase primary healthcare
physicians’ adherence to prescribing guidelines for patients
with a history of transient ischaemic attack (TIA) or AF
[28]. The outcome measure in this study did not distin-
guish between anticoagulant and antiplatelet prescribing.
Other randomised evaluations of implementation
strategies have been carried out with stroke survivors to
optimise secondary prevention [29-33]. These have
included few AF patients (n = 6 to n = 99) [29-33], and of
the two studies reporting outcomes for AF patients, nei-
ther found statistically significant improvements in anti-
coagulant prescribing [32,33].
Specialist decisional support for general practitioners
(GPs) merits further investigation. A recent evaluation
of a shared-care model for stroke survivors involved li-
aison between GPs and stroke specialists, facilitated via a
nurse specialist. The study found significant improve-
ments in the management of secondary stroke risk and,
for AF patients, a nonsignificant improvement in antic-
oagulation prescribing attributable to the intervention
[32]. However, the total number of AF patients in this
study was small (n = 32). While the multifaceted nature
of the study intervention precludes the identification of
effective components, it suggests that linking GPs with
stroke specialists could enhance clinical decision mak-
ing. An observational study also reported a significant
effect of collaborative involvement between specialists
and GPs on appropriate anticoagulation prescribing,
providing further support for the hypothesis that special-
ist input may be effective in improving the management
of AF patients [34].
In another study, known as DESPATCH, we are evalu-
ating the effect of expert decisional support to promote
the uptake of anticoagulation using feedback from clin-
ical experts in stroke medicine [35]. However, in the
DESPATCH study, decisional support is embedded
within a multifaceted intervention including written edu-
cational materials, three telephone academic-detailing
sessions, and a workshop/seminar. We have designed the
STOP STROKE in AF study to systematically assess the
impact of expert decisional support on the management
of AF in a national study.
Methods
Please see attached file (Additional file 1) for the study
flow diagram.
GP recruitment
We obtained contact details of GPs from a commercially
available database [36], which sources information from
professional colleges, medical directories, and state med-
ical boards that register all practising clinicians in Austra-
lia. After an initial pilot with 100 randomly selected GPs to
determine the likely participation rate, we undertook
recruitment in two phases, obtaining lists of 3,000 ran-
domly selected GPs from across Australia in 2010 and
2,501 in 2011 (with those selected in 2010 removed from
the sampling frame). GPs who were participating in an-
other implementation trial about AF we were carrying out
[37] were excluded from the randomly selected samples
(n= 10 in 2010 and n=13 in 2011).
GPs were mailed a brief introductory letter inviting
them to complete a registration form, to be returned by
fax or an enclosed business reply paid envelope, advising
us of their interest in an education program about stroke
prevention. During the first (i.e., in 2010) and second
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phases of recruitment (i.e., in 2011), we carried out two
randomised trials of response-aiding strategies, both of
which received ethics approval as amendments to the
main study protocol. During the first phase, a statistician
independent of the research team randomised 2,250 GPs
into three equal-sized groups (n = 750 for each group).
The first group was mailed the introductory letter and
registration form in an institutional 110 mm by
220 mm-sized envelope (DL-sized) with the university
logo and address printed in black and white on the top
left-hand corner. The second group was mailed the letter
and form in the institutional envelope and also received
complimentary copies of resources provided free of
charge by the National Stroke Foundation (NSF) of
Australia. The third group was also mailed the NSF
resources with their letter and form but received these
via an Australia Post “Express Post” envelope represent-
ing “priority mail”. The remaining 740 GPs were not
included in this trial and were mailed the introductory
letter and registration form at a different time point to
those selected to test response-aiding strategies. During
the second wave of recruitment, 2,488 GPs were ran-
domly divided to receive the cover letter and registration
form printed on pale yellow (n = 1,247) or white paper
(n = 1,240). Letters were mailed using the institutional
DL-sized envelopes with logo and address printed in
black and white. This trial was separately registered
(ACTRN12611000259943).
GPs who returned their registration forms were mailed
an information sheet and a consent form, advising that
consenting GPs would be invited to participate in an
educational session delivered by a medically trained peer
via telephone, after which they would be randomised to
receive specialist feedback about the de-identified patient
cases (see description of intervention below). GPs who
returned a signed consent form by fax or enclosed reply
paid envelope were then mailed educational materials in
advance of a telephone educational session to be deliv-
ered by medical peers. Only those GPs who complete the
telephone educational session, providing pretest data, are
considered recruited and eligible for randomisation. Dur-
ing the initial stages of the first recruitment phase (i.e., in
2010), GPs returning their registration form were tele-
phoned in advance of receiving the information sheet
and consent form, and those GPs not returning a consent
form within a minimum of two weeks were mailed a sec-
ond copy. However, due to resource constraints, this
follow-up protocol was abandoned.
Academic detailing
Enrolled GPs receive printed education materials (see
Additional file 2) prior to being contacted by a medically
trained peer who carried out a standardised telephone
educational session covering key issues concerning the
management of AF (see Additional file 3). Topics include
the epidemiology of AF [1-3], risk stratification using the
validated tools [37], and information about the benefits
and risks of antithrombotic medications used to manage
AF, including adjusted-dose warfarin and antiplatelet
medication, such as aspirin and/or clopidogrel [38-44].
During 2011, the information was revised to include in-
formation about a revised risk stratification scheme [45]
and dabigatran [46-48], a newly available fixed-dose anti-
coagulant that received regulatory approval in Australia
for stroke prophylaxis in AF in May 2011.
GPs were advised in advance of the telephone educa-
tional session to identify patients with AF who are over
the age of 65 and not receiving anticoagulation or for
whom anticoagulation management had presented diffi-
culties. GPs enrolled during the first phase of recruit-
ment (i.e., in 2010) were advised to select around three
or four patients for discussion with the medical peer,
while those recruited during the second phase (i.e.,
from 2011 onwards) were advised to select a minimum
of five patients.
At the conclusion of the telephone educational session,
the medically trained peer proceeded through a standar-
dised patient pro forma, collecting de-identified informa-
tion about patient demographics, stroke risk factors,
other comorbidities, current antithrombotic medica-
tions, and issues relevant to anticoagulation use. Medic-
ally trained peers calculated the patient’s CHADS2 score
with participating GPs, providing general feedback based
on evidence-based guideline recommendations, accord-
ing to patients’ CHADS2 scores [24]. The CHADS2 score
assigns two points for prior stroke or TIA and one point
each for the following risk factors: congestive heart fail-
ure, history of hypertension, age over 75, and diabetes.
Key safety messages about stroke risk in paroxysmal AF,
hypertension, and use of antithrombotic treatment in
patients with a history of spontaneous intracranial
haemorrhage were also communicated. From late 2011,
medical peers also communicated a safety alert issued by
the peak Australian drug regulatory body, the Therapeu-
tics Goods Administration (TGA), about the risks of
using dabigatran, a newly available oral anticoagulant, in
the elderly and in patients with renal impairment [49].
Pretest data collection
Before commencing the academic-detailing session,
medical peers noted GPs’ gender and asked participants
to report the number of doctors in their practice and
whether they were practising full-time or part-time.
Medical peers asked GPs whether they had any of the
following resources available to assist them in managing
AF patients receiving warfarin: a nurse to monitor and
recall patients when needed; automated or computerised
reminders for noting when patients need to have their
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International Normalised Ratios INR levels tested;
point-of-care INR testing; pathology service anticoagu-
lation management; or hospital clinical anticoagulation
management, practice-based register, or utilisation of a
formal Australian government program whereby phar-
macists visit patients to monitor compliance with med-
ications. A modified version of the Provider Decision
Process Assessment Instrument [50] measuring GP
levels of decisional conflict regarding warfarin use was
administered. GPs were asked to indicate their level of
agreement (agree, disagree, neither) to five statements
(‘Whether or not to prescribe warfarin is a difficult
decision to make’, ‘For most patients it is clear that war-
farin is the best treatment’, ‘It is often difficult to decide if
the benefits of warfarin outweigh the risks, or vice versa’,
‘Generally, patients fully appreciate the benefits of war-
farin’, ‘Generally, patients fully appreciate the risks of
warfarin’). Finally, medical peers asked GPs whether
they had participated in formal educational activities
about AF in the previous 12 months.
The de-identified patient pro forma document con-
tributed to the pretest patient-level data for this study.
Information on patient age and sex was first elicited.
GPs were then asked to clarify whether the patient
had paroxysmal or chronic AF (a response of unsure
was permitted) and whether the patient had underlying
valvular heart disease or nonvalvular AF. Medical peers
asked GPs to indicate if the patient had thyrotoxicosis
(yes/no/unsure). Relevant medical history ascertaining
stroke risk factors to enable calculation of the
CHADS2 score was elicited. History of myocardial in-
farction, peripheral artery disease, aortic plaque, coron-
ary artery disease, and high cholesterol/hyperlipidemia
was also noted, as was current smoking status.
Relevant comorbidities reflecting actual or perceived
contraindications to anticoagulation were also elicited.
These included the following: falls history (without and
without injury), a history of multiple falls, anaemia, re-
cent or current upper gastrointestinal (GI) bleeding
within the last month, history of upper GI bleeding, his-
tory of lower GI bleeding, history of GI bleeding (loca-
tion not specified), a treated cause of GI bleeding,
cerebral haemorrhage, hepatic insufficiency/moderate to
severe liver disease, impaired kidney function, chronic
dialysis, renal implantation, abnormal serum creatinine
(>200 ųmol/L), hepatic derangement on biochemical
testing, excessive alcohol intake (defined as eight or
more units per week), coagulopathy, thrombocytopaenia,
dementia or cognitive impairment (with and without
supervised care), insertion of coronary artery stent
(drug-eluting, bare metal, or stent of unknown type),
and nonadherence with medication or management.
Comorbidities assessing bleeding risk as described above
were derived from a standardised scheme [51]. GP
participants could nominate other comorbidities they
considered relevant for specialist feedback. The pro
forma elicited information on current antithrombotic
medications; previous use of anticoagulation with
adjusted-dose warfarin; and, where relevant, reasons for
not using warfarin, for ceasing warfarin, and adverse
events whilst receiving warfarin (minor bleeding not re-
quiring hospitalisation, major blood loss requiring hospi-
talisation, intracranial or intracerebral haemorrhage,
including subarachnoid haemorrhage; ischaemic stroke;
TIA or amaurosis fugax; sub-therapeutic INR levels;
supra-therapeutic INR levels; consistently unstable INR
levels). Rate- or rhythm-control medications, non-
steroidal anti-inflammatory drugs (NSAIDs) including
COX-2 inhibitors, paracetamol, alternative medications,
and other over-the-counter medications in current use
were also noted. From 2011 onwards, GPs were asked to
note, where relevant, adverse events whilst receiving antic-
oagulants other than warfarin (most likely dabigatran).
Randomisation
A statistician external to the study group is carrying out
randomisation after participants complete academic-
detailing sessions. Randomisation is being stratified by
the number of cases GPs identify (≤2 or >3). Results of
randomisation are communicated to the study coordin-
ator (MG) who assigns GPs to their respective groups.
The statistician involved in the analysis of the trial will
receive the randomisation schedule directly from the sta-
tistician carrying out randomisation. Block randomisa-
tion is being used to control for date of entry into the
trial. Block size will be disclosed to the study team only
during the write-up of results.
Expert decisional support
Medically trained peers reminded GPs that they will be
randomised to receive specialist feedback about patient
de-identified cases either prior to or after posttest evalu-
ation. They were advised to consider this component of
the intervention as an educational exercise and, there-
fore, should not have expectations of timely feedback
and should seek any urgently required advice through
their usual practices. Data from the de-identified pro
forma documents were mailed to MG, who entered the
data and summarised information into a one- to two-
page document that was forwarded to experts in either
neurology, cardiology and stroke. The experts provided
written information that was then mailed to GPs rando-
mised to receive expert decisional support prior to the
posttest phase of the study (see Additional file 4 for a
hypothetical example). Our model for delivering this as-
pect of the intervention was informed by an intervention
developed by McAlister et al., 2006 [52].
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Waiting list control
GPs randomised to the waiting list control group were
mailed a summary of patient de-identified information,
identical to the summary received by GPs randomised to
the intervention arm. These GPs also received a state-
ment summarising patient ischaemic stroke risk based
on the patient’s CHADS2 score. Therefore, patient sum-
maries were identical between groups, with the excep-
tion of specialist written feedback.
Posttest data collection
Posttest data collection is scheduled for approximately
12 weeks after GPs have received either the expert decisio-
nal feedback or, for those randomised to the waiting list
control group, the patient de-identified summary docu-
ment. GPs receive another copy of the patient de-identified
summary sheet (without expert feedback) attached to a
brief posttest questionnaire. For each patient, GPs are asked
to indicate current antithrombotic treatment from a list of
available choices (warfarin, aspirin, clopidogrel, aspirin and
clopidogrel, dipyridamole, dipyridamole with aspirin, dabi-
gatran, other antithrombotic for GP to specify, or no
antithrombotic) and, if currently receiving warfarin, to re-
port the last six INR test results and corresponding dates of
blood collection. In response to a checklist of items, GPs
are asked to specify reasons for any given patient not re-
ceiving anticoagulation (patient refusal/reluctance, history
of traumatic brain haemorrhage, history of spontaneous
brain haemorrhage, history of lower GI bleed, history of
upper GI bleed, falls history without injury, falls history
with injury, history of GI location not specified, age, cogni-
tive impairment, inadequate supervision at home, patient
nonadherence with medication, patient nonadherence with
monitoring, specialist doesn’t recommend anticoagulation,
patient at low risk of stroke, awaiting government subsid-
isation of fixed-dose anticoagulation with dabigatran, or
other reason which GPs are asked to specify).
Whether or not patients are receiving anticoagulation,
GPs complete an adapted version of the Provider Deci-
sion Process Assessment Instrument [50], consisting of
six items assessing GP levels of decisional conflict
regarding anticoagulation with adjusted-dose warfarin,
with an additional question asking GPs to indicate their
level of satisfaction with the current treatment. From
2011 onwards, the posttest evaluation included an add-
itional six questions assessing levels of decisional conflict
for a newly available fixed-dose anticoagulant, dabiga-
tran. Posttest data will be entered by personnel blinded
to group allocation.
Primary outcome
The primary outcome is defined as the proportion of
patients with AF who, at posttest, are reported by GPs
to be receiving anticoagulation.
Secondary endpoints
Appropriate antithrombotic treatment according to
stroke risk
In accordance with evidence-based guidelines [38-40],
we will use baseline CHADS2 scores in those patients
aged over 65 years to judge appropriateness of antith-
rombotic management. Specifically, patients over 65 years
of age with a baseline CHADS2 score of 0 will be consid-
ered to be managed appropriately if receiving aspirin,
while those with a baseline CHADS2 score of 2 or more
will be considered to be receiving appropriate antithrom-
botic treatment if receiving anticoagulation (either with
warfarin or dabigatran). Either anticoagulation or aspirin
will be considered appropriate in those with a baseline
CHADS2 score of 1. The expected few cases of patients
younger than 65 years of age will be excluded from
this analysis. However, a sensitivity analysis will be
carried out applying the CHADS2 score to patients
younger than 65 years of age, as above, in recognition of
inclusion criteria used in recent trials of antithrombotic
treatments that included patients younger than 65
where AF was associated with CHADS2 stroke risk fac-
tors [4-6].
Appropriate antithrombotic treatment according to stroke
risk incorporating quality-control criteria
In those patients receiving anticoagulation with warfarin,
we will only consider anticoagulation to be appropriate
for this outcome if GPs, when reporting the six most re-
cent INR results, report an INR result at least monthly
and where at least four of the six test results (or two-
thirds of results in cases where fewer than six are
reported) are within therapeutic range (i.e., within 2.0–
3.0). These criteria for appropriate anticoagulation are
based on local guidelines [44] and a consistently achieved
standard of ‘time in therapeutic range’ reported in clin-
ical trials [4-6], including one trial of general practice
patients with an average age of 81 years [6].
Further refinement of outcome definition
Combinations of antiplatelet therapies with or without
anticoagulation may diverge from standard guideline
recommendations but may nonetheless be appropriate
in the context of aspirin intolerance, patients with a his-
tory of coronary stenting, or in those affected by acute
coronary syndromes [42,43,53-55]. We will accept other
antiplatelet treatments, such as clopidogrel, dypridamole,
and combinations of these treatments, where aspirin
would have been considered the evidence-based treat-
ment. Where anticoagulation is considered the evidence-
based choice, we will not distinguish between cases
where anticoagulation is used alone or in combination
with other antithrombotics.
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Decisional conflict
Scores comprising the seven-item decisional conflict
scale, based on a previously validated measure [50]
adapted for use in our earlier work and in other studies
[13,14], will be summed to produce a total score,
whereby higher scores indicate higher levels of decisio-
nal conflict (range = 7 to 35). At the time of writing, war-
farin remains the only anticoagulant treatment that is
available to all Australian residents via Australia’s univer-
sal health insurance scheme ensuring government sub-
sidisation of medication. The fixed-dose anticoagulant
dabigatran has received regulatory approval for AF but
is not currently subsidised by the Australian govern-
ment. Consequently, the uptake of dabigatran is not
expected to be high, and we will restrict this outcome to
items assessing decisional conflict about warfarin only,
unless uptake of dabigatran is found to be common.
Sensitivity analyses
In cases that are lost to follow-up (for example, where
GPs do not return their posttest audit questionnaires),
we will reanalyse our primary and secondary outcomes
relating to prescribing behaviour, firstly, assuming no
change in antithrombotic management from baseline to
posttest and secondly, assuming the desired outcome
was not achieved.
Subgroup analyses
We will carry out subgroup analyses for our primary and
secondary outcomes according to the following vari-
ables: (a) baseline CHADS2 scores (0, 1, or ≥2); (b) pa-
tient age (<65 years, 65–74 years, 75–84 years,
≥85 years); (c) baseline anticoagulation use (yes versus
no); (d) patient sex.
Pretest comparisons between groups
We will compare groups on the numbers of patients
selected by GPs, patient sex, age (mean and median dif-
ferences and on categorical groupings <65 years, 65–74,
75–84, ≥85 years), CHADS2 scores (0, 1, ≥2, and mean
scores), and use of oral anticoagulation (current at pre-
test, previous use, or never used).
Sample size estimate
Our study was powered to detect a 15% difference in
anticoagulation rates between groups. We assumed a
baseline use of anticoagulation of 50% to produce antic-
onservative (i.e., larger) estimates of the required sample
size. In the absence of a design effect, whereby the sam-
ple size would be adjusted for clustering of patients by
GP, we required GPs to identify 170 patients per group
or 340 in total [56]. As patient cases were clustered by
GP, we adjusted our sample size estimate by the design
effect Deff = 1 + (m− 1)ρ [57], where m equals the average
cluster size and ρ equals the intraclass correlation coeffi-
cient. We have selected a value of m to produce anticon-
servative (i.e., larger) estimates of the required GP
sample, as the number of GPs needed will have a greater
effect on study resources and its feasibility than the
numbers of patient cases identified by GPs. Smaller
values of m will produce a sample size estimate requir-
ing greater numbers of GPs. Assuming an average clus-
ter size of three and selecting an intraclass correlation
coefficient of 0.029, informed by results from a previous
study [27], our anticipated design effect was 1.06 (i.e.,
1 + (3 – 1) × 0.029), producing a required total sample
size of 1.06 × 340 = 361. Assuming 20% of posttest audit
questionnaires are not returned by GPs, we require data
on 452 de-identified patient cases or 226 per group. If
GPs each select three patient cases on average, then we
will need to recruit 76 GPs per group (i.e., 226/3), or
152 in total.
Statistical analysis
Outcomes will be analysed according to the intention-
to-treat principle, whereby patients are analysed accord-
ing to the arm to which their GP cluster was allocated.
Clustering will be accounted for at the practice level
[57]. A p value of< .05 will be used to determine statis-
tical significance of results. Analyses will be carried out
by a statistician blinded to group allocation.
Ethics approval
The Human Research Ethics Committee of the Univer-
sity of New South Wales has approved the study
(UNSW HREC Reference Number 07067).
Discussion
Long-term anticoagulation for AF remains the treatment
of choice to prevent stroke in most people with AF. The
STOP STROKE in AF study has an active ‘control’. In-
formation is delivered via academic detailing with tai-
lored feedback about risk stratification and guideline
recommendations. The addition of expert decisional
support in our intervention arms allows for a direct test
of this component on GP self-reported patient manage-
ment. The national geographical reach of the study and
feasible delivery of the intervention, via telephone and
mail, are innovations of the study.
Until recently, warfarin has been the only oral anti-
coagulant available for managing AF. Two fixed-dose
anticoagulants, dabigatran [46,47] and rivoroxaban [58],
have received approval for stroke prophylaxis in AF by
the US Federal Drug Administration (FDA). Apixaban
[59], another fixed-dose anticoagulant, is due to be
reviewed by the FDA in 2012. It is unclear whether the
advent of new drugs will improve anticoagulation rates.
In practice, uptake of dabigatran, the first FDA-approved
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fixed dose oral anticoagulant, has been described as ‘dis-
appointing’, with an estimated 10% of AF patients using
the drug in the United States [60]. The cost of the drug,
the need for twice-daily dosing, a short shelf-life, the
lack of an antidote to reverse acute bleeding, the inabil-
ity to determine the anticoagulation effects of dabiga-
tran, and the increased risk of GI bleeding, dyspepsia,
discontinuation, and possibly myocardial infarction,
when compared with warfarin, may limit its broader up-
take [58]. Recent warnings from regulators in Australia
[48] and the United States [61] have emphasised safety
concerns about dabigatran, particularly in those with
renal impairment and in elderly patients aged over
75 years. In Australia, AF became an approved indica-
tion for dabigatran by the local government regulator,
the TGA, after which the company manufacturing the
drug offered doctors free medication for a limited period
of time, or until the drug became subsidised by the Aus-
tralian government (whichever occurred first). The Aus-
tralian government has thus far declined the company’s
application to subsidise the drug. Federal agencies in
Australia are currently undertaking a further review of
the costs and benefits of the new drug and defining the
circumstances in which warfarin may be more cost ef-
fective. Other fixed-dose anticoagulants that may come
to market in the near future, specifically rivaroxaban and
apixaban, share some drawbacks of dabigatran; all three
lack an antidote to reverse acute bleeding, and apixaban
also requires twice-daily dosing.
Prescribing behaviour seems difficult to shift. The
South London secondary prevention programme, also
called Stop Stroke, enrolled 523 stroke survivors, 99 of
whom had AF. Patients were randomised to receive
‘keeping well plans’ summarising risk factors and man-
agement strategies, including evidence-based prescribing
for managing blood pressure, diabetes, and AF, that were
updated over a 12-month period [33]. The intervention
had no effect on any of the study outcomes, including
anticoagulant prescribing for AF patients.
Clinician fears about the side effects of anticoagulation
appear to have greater influence on anticoagulant pre-
scribing than do concerns about stroke risk. Clinicians
are less likely to prescribe anticoagulation in patients
with AF if one of their AF patients receiving anticoagu-
lation is hospitalised for a major bleed, yet prescribing
behaviour is not influenced if untreated AF patients are
hospitalised for an ischaemic stroke [62]. In our national
Australian survey [13,14], GPs with prior experiences of
a haemorrhagic stroke in AF patients report a heigh-
tened sense of responsibility for that outcome. In con-
trast, GPs with untreated AF patients who had a stroke
were no more likely to feel responsible for this outcome
than other GPs. Further, our survey showed that GPs
appeared overly cautious in prescribing anticoagulation
in the presence of any perceived risk of bleeding, even
where treatment benefits clearly outweighed the risk of
harm. Other Australian surveys show that GPs are reluc-
tant to prescribe anticoagulation for nonvalvular atrial
fibrillation in the elderly or in the presence of perceived
bleeding risks, which would not contraindicate anticoa-
gulation according to available evidence [15-17].
The STOP STROKE in AF study aims to redress clin-
ician wariness and concerns over the use of anticoagula-
tion and support effective decision making to build
practitioner confidence and increase the appropriate up-
take of anticoagulation in AF.
In addition to our own research, we are aware of one
other Australian study evaluating a risk assessment tool
in general practice for improving the management of AF
[63,64]. It is hoped that these studies will collectively
identify effective implementation strategies to better in-
form GPs on AF management, closing the evidence–
practice gap in Australia and elsewhere.
Progress
Required numbers of GPs have been recruited. We ex-
pect posttest data collection to be completed in 2012.
Results are expected in 2013.
Additional files
Additional file 1: Consort flow diagram.
Additional file 2: Summary of written information mailed
to all GPs.
Additional file 3: Content summary of academic detailing session.
Additional file 4: Example of patient summary and expert
feedback.
Competing interests
The authors state they have no competing interests to declare.
Acknowledgements
Randomisation for the STOP STROKE in AF is being performed by Patrick
McElduff, Clinical Research Design, IT and Statistical Support Unit (CReDITSS),
University of Newcastle. Chris Goumas, Data Analyst, School of Public Health
and Community Medicine, The University of New South Wales, and Anthony
Yeo, Biostatistician, Ingham Institute, carried out randomisation for the
response-aiding strategies for the first and second phase of recruitment,
respectively. The STOP STROKE in AF trial is supported by the BUPA
Foundation, Australia. MG was supported by an NHMRC Public Health Post-
Doctoral Training Fellowship (#301136) at the time of writing the submission
for project funding and was supported by a Commonwealth Department of
Health and Ageing, Primary Health Care Research, Evaluation and
Development Mid-Level Career Research Fellowship from September 2007 to
September 2011. The opinions expressed in this publication do not
necessarily reflect those of the Commonwealth of Australia, which does not
accept any liability for loss, damage, or injury incurred by the use of or
reliance on the information contained herein. The funding bodies had no
role in the design of the study, the writing of this manuscript, or in the
decision to submit the manuscript for publication. We thank the GPs who
have participated in the study and gratefully acknowledge The National
Stroke Foundation of Australia for providing free resources for use in our trial
of response-aiding strategies. The STOP STROKE in AF content experts were
Associate Professor John M Worthington and Professor Dominic Leung. The
STOP STROKE in AF specialist expert committee included Associate Professor
Gattellari et al. Implementation Science 2012, 7:63 Page 7 of 9
http://www.implementationscience.com/content/7/1/63
David Blacker, Dr Emma Blackwood, Professor Christopher Bladin, Associate
Professor Brian Chambers, Associate Professor Dennis Cordato, Dr Andy
Evans, Professor Dominic Leung, Associate Professor Stephen Read, Professor
David Schultz, and Associate Professor John M Worthington. The STOP
STROKE in AF academic detailers/medical peers were Drs. Jemima Grant,
Kate Johnston, Amelia Lem, Declan Mulvaney, Jay Ramanathan, Brian
Simmons, and Anna Windsor. The project management team consisted of
Melina Gattellari, Laura Morgan-Deller (past), and Catherine Johnson (past).
Author details
1Ingham Institute, Liverpool, Australia. 2School of Public Health and
Community Medicine, The University of New South Wales, Sydney, Australia.
3South Western Sydney Clinical School, The University of New South Wales,
Sydney, Australia. 4Department of Neurology, Liverpool Health Service, South
Western Sydney Local Health Network, Liverpool, Australia. 5Department of
Cardiology, Liverpool Health Service, South Western Sydney Local Health
Network, Liverpool, Australia.
Authors’ contributions
JMW initiated the group’s interest in developing an intervention in general
practice to reduce stroke risk in patients with atrial fibrillation. MG is the lead
investigator on the study. MG and JMW had major input into study design
and conceptualisation and cowrote the protocol for publication. NZ and DYL
provided input into study protocol at the time of its conceptualisation. JMW
and DYL led the expert decisional-support component of the intervention
and informed outcome assessment. JMW prepared authored information
resources. All authors reviewed and provided feedback on the protocol. All
authors have read and approved the final submission.
Received: 9 May 2012 Accepted: 6 July 2012
Published: 6 July 2012
References
1. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL: Atrial fibrillation
and mortality in an elderly population. ANZ Med 1989,
19:321–326.
2. Wolf PA, Abbot RD, Kannel WB: Atrial fibrillation as an independent risk
factor for stroke: the Framingham study. Stroke 1991, 22:983–988.
3. Gattellari M, Goumas C, Aitken R, Worthington JM: Outcomes for patients
with ischaemic stroke and atrial fibrillation: The PRISM study (A Program
of Research Informing Stroke Management). Cerebrovasc Dis 2011,
32:370–382.
4. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to
prevent stroke in patients who have nonvalvular atrial fibrillation. Ann
Intern Med 2007, 146:857–867.
5. Hart RG, Pearce LA, Aguilar MI: Adjusted-dose warfarin versus aspirin for
preventing stroke in patients with atrial fibrillation (author’ reply). Ann
Intern Med 2007, 147:591.
6. Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH: Warfarin
versus aspirin for stroke prevention in an elderly community population
with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the
Aged Study, BAFTA): A randomised controlled trial. Lancet 2007,
370:493–503.
7. Olgilvie IM, Welner SA, Cowell W, Lip GY: Characterization of the
proportion of untreated and antiplatelet therapy treated patients with
atrial fibrillation. Am J Cardiol 2011, 108:151–61.
8. Olgilvie IM, Newton N, Welner SA, Cowell W, Lip GYH: Underuse of oral
anticoagulants in atrial fibrillation. A systematic review. Am J Med 2010,
123:638–645.
9. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM: Optimizing the use
of antithrombotic therapy for atrial fibrillation in older people: a
pharmacist-led multidisciplinary intervention. J Am Geriatric Soc 2005,
53:1912–20.
10. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK:
Potentially preventable strokes in high-risk patients with atrial fibrillation
who are not adequately anticoagulated. Stroke 2009, 40:235–240.
11. Ahmad O, Ahmad KE, Dear KBG, Harvey I, Hughes A, Lueck CJ: Atrial
fibrillation and anticoagulation in a stroke unit population. Internal
Medicine Journal 2009, 39:752–56.
12. Pugh D, Pugh J, Mead GE: Attitudes of physicians regarding
anticoagulation for atrial fibrillation: a systematic review. Age and Ageing
2011, 40:675–83.
13. Gattellari M, Worthington J, Zwar N, Middleton S: Barriers to the use of
anticoagulation for non-valvular atrial fibrillation (NVAF): a representative
survey of Australian family physicians. Stroke 2008, 39:227–230.
14. Gattellari M, Worthington JM, Zwar NA, Middleton S: The management of
non-valvular atrial fibrillation (NVAF) in Australian general practice:
bridging the evidence-practice gap. A national, representative postal
survey. BMC Fam Pract 2008, 9:62.
15. Shen A, Cordato D, Ng J, Hung WT, Kokkinos J, Karr M, Yin Chan DK:
Anticoagulant usage for primary stroke prevention: a general
practitioner survey in local areas of metropolitan Sydney. J Clin Neurosci
2008, 15:166–71.
16. Peterson GM, Boom K, Jackson SL, Vial JH: Doctors’ beliefs on the use of
antithrombotic therapy in atrial fibrillation: identifying barriers to stroke
prevention. Internal Medicine Journal 2002, 32:15–23.
17. Arendts G, Krishnaraj M, Paull G, Rees D: Management of atrial fibrillation
in the acute setting: findings from an Australasian survey. Heart, Lung &
Circulation 2010, 19:423–7.
18. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M: Are
atrial fibrillation patients receiving warfarin in accordance with stroke
risk? Am J Med 2010, 123:446–53.
19. Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG,
Bianchi C, Cricelli C: A national survey of the management of atrial
fibrillation with antithrombotic drugs in Italian primary care. Thromb
Haemost 2010, 103:968–75.
20. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G, Italian
Federation of Anticoagulation Clinics: Bleeding risk in very old patients on
vitamin K antagonist treatment: results of a prospective collaborative
study on elderly patients followed by Italian Centres for Anticoagulation.
Circulation 2011, 124:769–71.
21. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N,
Go AS: The net clinical benefit of warfarin: anticoagulation in atrial
fibrillation. Ann Intern Med 2009, 151:297–305.
22. Garwood CL, Corbett TL: Use of anticoagulation in elderly patients with
atrial fibrillation who are at risk for falls. Annals of Phamacotherapy 2008,
42:523–32.
23. Man-Son-Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic
therapy for elderly patients with atrial fibrillation who are at risk for falls.
Arch Intern Med 1999, 159:677–85.
24. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW:
Incidence of intracranial hemorrhage in patients with atrial fibrillation
who are prone to fall. Am J Med 2005, 118:612–7.
25. McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D, Majumdar
PG, Cox JL, Fradette M, for the Decision Aid in Atrial Fibrillation (DAAFI)
Investigators: Impact of a patient decision aid on care among patients
with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ 2005,
173:496–501.
26. Jackson SL, Peterson GM, Vial JH: A community-based educational
intervention to improve antithrombotic drug use in atrial fibrillation. Ann
Pharmacother 2004, 38:1794–1799.
27. Ornstein S, et al: A multimethod quality improvement intervention to
improve preventive cardiovascular care: a cluster randomized trial. Ann
Intern Med 2004, 141:523–32.
28. Wright J, Bibby J, Eastham J, Harrison S, McGeorge M, Patterson C, Price N,
Russell D, Russel I, Small N, Walsh M, Young J: Multifaceted
implementation of stroke prevention guidelines in primary care:
cluster-randomised evaluation of clinical and cost effectiveness.
Qual Saf Health Care 2007, 16:51–59.
29. Allen KR, Hazelett S, Jarjoura D, Wickstrom GC, Hua K, Weinhardt J, Wright K:
Effectiveness of a postdischarge care management model for stroke and
transient ischemic attack: a randomized trial. Journal of Stroke and
Cerebrovascular Disease 2001, 11:88–98.
30. Banet GA, Felchlia MA: The potential utility of a shared medical record in
a ‘first-time’ stroke population. J Vasc Nurs 1997, 15:29–35.
31. Ellis G, Rodger J, McAlpine C, Langhorne P: The impact of stroke nurse
specialist input on risk factor modification: a randomised controlled trial.
Age Ageing. 2005, 34:389–392.
32. Joubert J, Reid C, Barton D, Cumming T, McLean A, Joubert L, Barlow J,
Ames D, Davis S: Integrated care improves risk-factor modification after
Gattellari et al. Implementation Science 2012, 7:63 Page 8 of 9
http://www.implementationscience.com/content/7/1/63
stroke: initial results of the Integrated Care for the Reduction of
Secondary Stroke model. J Neurol Neurosurg Psychiatry 2009, 80:279–284.
33. Wolfe CDA, Redfern J, Rudd AG, Grieve AP, Heuschmann PU, McKevitt C:
Cluster randomized controlled trial of a patient and general practitioner
intervention to improve the management of multiple risk factors after
stroke. Stop Stroke. Stroke. 2010, 41:2470–2476.
34. Choudhry NK, Soumerai SB, Normand SLT, Ross Degnan D, Laupacis A,
Anderson GM: Warfarin prescribing in atrial fibrillation: the impact of
physician, patient and hospital characteristics. Am J Med 2006,
119:607–615.
35. Gattellari M, Leung DY, Ukoumunne OC, Zwar N, Grimshaw J, Worthington
JM: Study protocol: The DESPATCH study: Delivering stroke prevention
for patients with atrial fibrillation- a cluster cluster randomised
controlled trial. Implement Sci 2011, 6:48.
36. AMPCo Direct. http://www.ampcodirect.com.au/DynamicPages.asp?
cid=11&navid=2 last accessed January2, 2012.
37. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ:
Validation of clinical classification schemes for predicting stroke: results
from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864–70.
38. Hankey GJ, on behalf of the National Blood Pressure Advisory Committee of
the National Heart Foundation: Non-valvular atrial fibrillation and stroke
prevention Position Statement. MJA 2001, 174:234–239.
39. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA,
Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN,
Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA, Ezekowitz MD,
Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG,
Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger
SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM,
Stevenson WG, Tarkington LG, Yancy CW, American College of Cardiology
Foundation/American Heart Association Task Force: 2011 ACCF/AHA/HRS
focused updates incorporated into the ACC/AHA/ESC 2006 guidelines
for the management of patients with atrial fibrillation: a report
of the American College of Cardiology Foundation/American Heart
Association Task Force on practice guidelines. Circulation 2011,
123:e269–367.
40. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of
Chest Physicians: Antithrombotic and thrombolytic therapy for ischemic
stroke: American College of Chest Physicians Evidence-based Clinical
Practice Guidelines (8th Edition). Chest 2008, 13:630S–669S.
41. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM: Position
statement. Wafarin reversal: consensus guidelines, on behalf of the
Australasian society of thrombosis and haemostasis. MJA 2004, 181:492–497.
42. The ACTIVE Investigators: Effect of clopidogrel added to aspirin in
patients with atrial fibrillation. N Eng J Med 2009, 360:2066–2078.
43. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart
R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S:
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation
in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention
of Vascular Events (ACTIVE W): a randomized controlled trial.
Lancet 2006, 367:1903–1912.
44. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM, On behalf of the
Australasian Society of Thrombosis and Haemostatis: Position statement.
Consensus guidelines for warfarin therapy. Recommendations from the
Australasian Society of Thrombosis and Haemostatis. Medical Journal of
Australia 2000, 172:600–605.
45. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM: Refining clinical risk
stratification for predicting stroke and thromboembolism in atrial
fibrillation using a novel risk factor based approach: the Euro Heart
Survey on atrial fibrillation. Chest 2010, 137:263–272.
46. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A,
Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D,
Zhu J, Diaz R, Lewis BS, Darious J, Deiner HC, Joyner CD, Wallentin
L: RE-LY Steering Committee and Investigators. Dabigatra versus
warfain in patients with atrial fibrillation. N Engl J Med 2009,
361:1139–51.
47. Connolly SJ, Ezekowitz MD, Yusyf S, Reilly PA, Wallentin L, for the Randomised
Evaluation of Long-term Anticoagulation Therapy Investigators: Newly
identified events in the RE-LY trial. N Engl J Med 2010, 363:1875–1876.
48. National Prescribing Service: Dabigatran (Pradaxa). NPS Radar Review. http://
www.nps.org.au/news_and_media/media_releases/repository/
Dabigatran_Pradaxa_NPS_RADAR_Review. Last accessed January 2, 2012.
49. Therapeutic Goods Administration. http://www.tga.gov.au/safety/alerts-medicine-
dabigatran-111005.htm Last accessed Janaury 2, 2012.
50. Dolan JG: Method for evaluating health care providers’ decision making:
the Provider Decision Process Assessment Instrument. Medical Decision
Making 1991, 19:38–41.
51. Lip GYH, Frison L, Halperin JL, Lane DA: Comparative validation of a novel
risk score for predicting bleeding risk in anticoagulated patients with
atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition Labile INR, Elderly,
Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57:173–80.
52. McAlister FA, Fradette M, Graham M, Majumdar SR, Ghali WA, Williams R,
Tsuyuki RT, McMeekin J, Grimshaw J, Knudtson ML: A randomized trial to
assess the impact of opinion leader endorsed evidence summaries on
the use of secondary prevention strategies in patients with coronary
artery disease: The ESP-CAD trial protocol (NCT00175240). Implement Sci
2006, 1:11.
53. Paiken JS, Mehta SR, Eikelboom JW: Role of triple antithrombotic therapy
in patients with atrial fibrillation and coronary artery stents. Medical
Journal of Australia 2010, 192:487–488.
54. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll
N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ,
Poulsen HE, Kober L, Torp-Pedersen C: Risk of bleeding with single, dual,
or triple therapy with warfarin, aspirin, and clopidogrel in patients with
atrial fibrillation. Arch Intern Med 2010, 170:1433–41.
55. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB,
Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY: Antithrombotic
therapy in patients treated with oral anticoagulation undergoing
coronary artery stenting. An expert consensus document with focus on
atrial fibrillation. Annals of Medicine 2008, 40:428–36.
56. Dupont WD, Plummer WD: Power and sample size calculations: a review
and computer program. Control Clin Trials 1990, 11:116–28.
57. Murray DM: Design & analysis of group randomized trials. NY: Oxford
University Press; 1998.
58. Patel MR, Maheffrey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz
SD, Fox KA, Califf RM: Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med 2011, 365:883–91.
59. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-
Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD,
Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S,
Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS,
Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L,
ARISTOTLE Committees and Investigators: Apixaban versus warfarin in
patients with atrial fibrillation. New England Journal of Medicine 2011,
365:981–92.
60. Zoller ML: Dabigatran’s first A-Fib year starts warfarin’s decline. eCardiology
News. http://www.ecardiologynews.com/news/arrhythmias-
electrophysiology/single-article/dabigatran-s-first-a-fib-year-starts-warfarin-s-
decline/446ecf58b7.html November 13, 2011. Last accessed January 2, 2012.
61. Federal Drugs Administration: Federal Drugs Administration. http://www.fda.gov/
Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/
ucm282820.htm Last accessed January 2, 2012.
62. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normant SLT,
Soumerai SB: Impact of adverse events on prescribing warfarin in patients
with atrial fibrillation: matched pair analysis. BMJ 2006, 332:141–145.
63. Bajorek BV, Masood N, Krass I: Optimising the utilisation of antithromnotic
therapy for stroke prevention in AF, Development and evaluation of a
computerised antithrombotic risk assessment took (CARAT), Poster
presentation 20th European Stroke Conference. Hamburg, Germany:
May 24-27, 2011. http://www.esc-archive.eu/hamburg11/Ongoing%20Trials
%20ESC%20Hamburg%202011.pdf (Last accessed April 15 2012).
64. Bajorek BV, Masood N, Krass I: Development of a computerised
antithrombotic risk assessment tool (CARAT) to optimise therapy in
older persons with atrial fibrillation. Australasian Journal on Ageing 2012,
31:102–09.
doi:10.1186/1748-5908-7-63
Cite this article as: Gattellari et al.: Supporting Treatment decision
making to Optimise the Prevention of STROKE in Atrial Fibrillation: The
STOP STROKE in AF study. Protocol for a cluster randomised controlled
trial. Implementation Science 2012 7:63.
Gattellari et al. Implementation Science 2012, 7:63 Page 9 of 9
http://www.implementationscience.com/content/7/1/63
